Collegium Pharmaceutical's CEO to Present at the Cowen & Company 33rd Annual Health Care Conference in Boston on March 6, 2013

CANTON, Mass., Feb. 28, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the company's President and CEO, Michael Heffernan, will present the company's corporate overview on Wednesday, March 6, 2013 at 11:00 am EST at the Cowen & Company 33^rd Annual Health Care Conference. The conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts.

The Company's lead development program is Oxycodone DETERx^® (COL-003), a tamper-resistant, extended-release oxycodone product utilizing its proprietary DETERx^® technology. The Oxycodone DETERx^® formulation was specifically designed to provide and preserve extended release of the active ingredient following the most common methods of product tampering employed by drug abusers (e.g., crushing, chewing, heating for IV injection, etc.). The product is currently in the final stage of clinical development and has been designated Fast Track Status by the FDA due to its potential to address the problem of prescription drug abuse, a major public health issue in the U.S.

About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx^® formulation platform for the treatment of chronic pain. The DETERx^® oral drug delivery technology provides extended release delivery, unique tamper-resistant properties, and flexible dose administration options. For more information, visit the Company's website at www.collegiumpharma.com.

Contact:

Michael Heffernan, President
Collegium Pharmaceutical, Inc.
781-713-3699
[email protected]

SOURCE Collegium Pharmaceutical, Inc.